European Pharmaceutical Review

APRIL 11, 2024

Globally, the pharmaceutical sector emitted around 52 megatonnes of CO 2 in 2015, the most recent period for which detailed numbers are available. 1 Every major pharmaceutical manufacturer in the UK and Ireland is investing in making their operations and supply chains more environmentally friendly. 2019 Mar;214:185–94.

Manufacturing 105

Manufacturing Pharmaceutical Engineering Pharmaceutical manufacturing 105

European Pharmaceutical Review

AUGUST 9, 2022

Burkholderia species are one of the primary causes of non-sterile pharmaceutical product recalls and accounted for 45.3 percent of recalls recorded by the US Food and Drug Administration (FDA) between 2012 and 2019. Daddy Gaoh et al.

Food and Drug Administration 98

Food and Drug Administration Pharmaceutical products Pharmaceutical Pharmaceutical manufacturing 98

European Pharmaceutical Review

AUGUST 31, 2023

[pharmaceutical companies] must take measures to manage antibiotic waste across the manufacturing supply chain” 2023 has so far, delivered a spectrum of change for antibiotic manufacturers across the pharmaceutical industry, from supply chain issues through to regulatory opportunities.

Manufacturing 97

Manufacturing Medicine Management Pharmaceutical 97

European Pharmaceutical Review

JULY 25, 2022

Consequently, pharmaceutical manufacturers risk their reputation if impersonating products fail to deliver the expected quality or health impact. For manufacturers, this allows for greater protection of products courtesy of real-time tracking data and the ability to refine and secure supply chains by spotting weak links.

Pharmaceutical 104

Pharmaceutical Medicine Pharmaceutical manufacturing Manufacturing 104

pharmaphorum

OCTOBER 26, 2022

Chiesi has proven its dedication to global public health through its designation as a certified Benefit Corporation (B Corp) since 2019. The status isn’t awarded lightly and Chiesi is the largest pharmaceutical manufacturer to be named a B Corp. “We But rare diseases are a particularly important and challenging focus area.

Patients 77

Patients Pharma Consulting Transportation 77

PM360

DECEMBER 20, 2023

However, manufacturers can start collecting real-world evidence from the early access programs in the pilot zones to enhance the drugs clinical value in local population and support its regulatory application for mainland China. National Reimbursement Drug List (NRDL) by NHSA NRDL is the only reimbursed list for BMI plan in China.

Marketing 105

Marketing Insurance Medical Manufacturing 105

Pharmaceutical Technology

DECEMBER 6, 2022

Despite the current emphasis on biologic medicines, small molecule drugs still dominate the pharmaceutical manufacturing world. Within the small molecule landscape, several trends are shaping the industry’s future, one of the most notable being the rise of high-potency active pharmaceutical ingredients (HPAPIs).

Manufacturing 52

Manufacturing Pharmaceutical Pharmaceutical manufacturing Safety 52